Hengrui presented Phase II results for HRS-7535. The 36-week trial (n=235) evaluated this oral small molecule in obese/overweight non-diabetic patients (BMI 28 to 40 kg/m²).

At week 26, the 180 mg dose achieved a placebo-adjusted weight reduction of 6.87% (P<0.0001). By week 36, this group showed 9.50% weight loss (vs 1.40% placebo), with 35.4% participants losing ≥10% body weight.

Safety data indicated 87.2% to 95.8% treatment-emergent adverse events (mainly mild-to-moderate nausea [16.7%-54.2%], diarrhoea [16.7%-21.7%] and vomiting [15.7%-37.5%]). No liver enzyme elevations were observed.